Navigation Links
Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring
Date:11/30/2007

New HIV Viral Load Assay Developed Specifically for Resource-Limited

Settings Joins Global Procurement Consortium

UPPSALA, Sweden, November 30 /PRNewswire/ -- Cavidi AB, a producer of medical diagnostic products, today announced an agreement with the Clinton Foundation HIV/AIDS Initiative (CHAI). Under the agreement, Cavidi's ExaVir(TM) Load assay will be immediately available to members of CHAI's Procurement Consortium at a discounted price. With more than 70 developing countries in the consortium, the agreement is a significant step in making viral load monitoring more accessible to HIV-positive patients in the developing world.

Viral load monitoring is essential for the proper management of HIV-positive patients being treated with antiretroviral drugs (ARVs). The test helps doctors use ARVs more effectively to extend a patient's length and quality of life, limit the development of viral resistance and minimize waste of medication. "Viral load testing is an essential part of HIV management. As more people in the developing world gain access to ARVs, it's important that access to viral load testing keeps pace," said Cavidi CEO Martyn Eales. "It's Cavidi's goal to make monitoring more accessible in all countries. I'm very pleased with our partnership with President Clinton's Foundation because it brings us closer to reaching that goal."

Although viral load monitoring has been a standard part of treatment in developed countries, it has been considered impractical for use in developing nations where HIV infection is most widespread. That is because traditional viral load tests are expensive and require technically advanced laboratory facilities. ExaVir Load is the first HIV viral load test designed to overcome these obstacles. Several independent studies have shown the assay to be as accurate and reliable as any other commercially available test, with the added benefit of being able to detect all known subtypes of HIV. This is particularly important in regions like sub-Saharan Africa where different HIV subtypes are common.

"We face a global HIV/AIDS emergency and laboratory tests are a vital component of HIV/AIDS care and treatment," said Deepak Verma, CEO of CHAI. "The success of treatment programs is dependent not only on the ability to diagnose and qualify HIV-positive patients for therapy, but also to monitor treatment efficacy and safety and to manage disease treatment. We are pleased to work with Cavidi and commend them for helping to make HIV viral load tests available at lower cost to members of our Procurement Consortium."

About Cavidi AB

Cavidi AB was founded by leading virologists at Uppsala University in Sweden in 1984. The company's mission is to make medical diagnostics more accessible in those parts of the world where resources and infrastructure are limited. Their products include ExaVir Load and ExaVir Drug, which are used in HIV management. For press photos and more information, please visit, http://www.cavidi.com

About Clinton Foundation HIV/AIDS Initiative (CHAI)

Since 2002, CHAI has been assisting countries in implementing large-scale, integrated HIV/AIDS care and treatment programs. It partners with 28 countries in Africa, the Caribbean and Asia. Individual governments take the lead and CHAI provides technical assistance, mobilizes human and financial resources, and facilitates the sharing of best practices across projects. CHAI also provides access to reduced prices for HIV/AIDS drugs and diagnostics to more than 70 countries.
For more information, please visit: http://www.clintonfoundation.org

For further information and interview requests please contact:

Kajsa Lowenhielm

Information Manager, Cavidi AB

Mobile: +46-709-42-90-50

kajsa@cavidi.se


'/>"/>
SOURCE Cavidi AB
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New Investors Fund Expansion of Cavidi AB
2. Pot bellies linked to early signs of cardiovascular disease
3. MSU engineering team designs innovative medical device
4. Jump in Youth Suicide Prompts National Childrens Charity KidsPeace to Issue Tips on Prevention, Warning Signs
5. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
6. Gov. Blagojevich Signs Bill Improving Illinois Mental Illness Treatment Law
7. A new technology for cancer screening listens for the signs of cancer
8. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
9. Pearson VUE Signs Exclusive Contract with Educational Resources, Inc.
10. Former Ronco President Tim Dupler Signs International Direct Sales and Marketing Contract with Natural Nutrition
11. KARL LAGERFELD SAS Signs Global Eyewear License Agreement With Marchon Eyewear, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... The Anaheim Hills office ... First National Capital has added 10 new sales professionals over the past 6 months ... by 15 additional new hires over the course of 2017. , “This new ...
(Date:3/27/2017)... Orange, Texas (PRWEB) , ... March 27, 2017 ... ... celebration at the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to ... giveaways and will be an opportunity for area-residents to celebrate two great years ...
(Date:3/26/2017)... ... March 26, 2017 , ... Local physician Dr. Justin ... a prestigious award honoring the top influencers on RealSelf—the most trusted online destination ... doctors and clinics. , In 2016, more than 82 million people visited RealSelf ...
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter ... the same time by providing Prehospital Trauma Life Support (PHTLS) course scholarships to ... premier prehospital trauma education developed in cooperation with the American College of Surgeons ...
(Date:3/24/2017)... ... ... The Radiology Business Management Association (RBMA) has named the nine winners ... year, are among the most prestigious in radiology marketing because a panel of radiology ... recognize achievements in both large budget (over $5,000) and small budget (under $5,000) campaigns. ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
(Date:3/27/2017)... 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), a ... liver diseases in children, today reported financial results ... December 31, 2016 and provided an update on ... to make progress during the fourth quarter of ... our non-human primate safety study, and with our lead ...
Breaking Medicine Technology: